Latest Velan Inc Sub Vtg (VLNSF) Headlines Velan Inc.

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Latest Velan Inc Sub Vtg (VLNSF) Headlines

Velan Inc. Reports its Third Quarter 2013/14 Financial Results
Marketwire - Thu Jan 09, 3:01PM CST
Velan Inc. (TSX: VLN) (the "Company"), a world-leading manufacturer of industrial valves, announced today its financial results for its third quarter ended November 30, 2013.

Velan Inc.: Announcement
Marketwire - Fri Jan 03, 11:30AM CST
Velan Inc. (TSX: VLN) today announced that on Thursday, January 9, 2014, it will release third quarter results ended November 30, 2013.

Velan Inc.: 2013 Normal Course Issuer Bid
Marketwire - Thu Oct 17, 4:03PM CDT
Velan Inc. (the "Corporation") (TSX: VLN) announced today that it has received approval of the Toronto Stock Exchange ("TSX"), to proceed with a normal course issuer bid. Under the bid, the Corporation may purchase up to 100,000 Subordinate Voting Shares (the "Shares") of the Corporation, representing approximately 1.57% of the issued Shares of such class as at October 10, 2013. The average daily trading volume for the 6-month period preceding October 1, 2013 is 3,367 Shares. In accordance with TSX rules, the Corporation may repurchase up to 1,000 Shares on a daily basis. The bid will commence on October 22, 2013 and terminate on October 21, 2014 or on such earlier date as the Corporation may complete its purchases pursuant to the bid. The Shares will be purchased on behalf of the Corporation by a registered broker through the facilities of TSX or alternative Canadian trading platforms. The price paid for the Shares will be the market price at the time of the acquisition, and the number of Shares purchased and the timing of any such purchases will be determined by the Corporation. All Shares purchased by the Corporation will be cancelled. As at October 10, 2013, the Corporation had 6,357,201 Shares outstanding. During the past 12 months, 29,300 Shares were purchased by the Corporation at a weighted average price of $11.48.

Velan Inc. Reports its Second Quarter 2013/14 Financial Results
Marketwire - Wed Oct 09, 3:01PM CDT
Velan Inc. (TSX: VLN) (the "Company"), a world-leading manufacturer of industrial valves, announced today its financial results for its second quarter ended August 31, 2013.

Velan Inc.: Results of Annual Meeting of Shareholders
Marketwire - Thu Jul 11, 3:56PM CDT
Velan Inc. (the "Corporation") (TSX: VLN) announced today that each director nominee listed in the Management Proxy Circular dated May 28, 2013 was elected as Director of the Corporation during the Annual Meeting of the Shareholders held earlier today in Montreal, Quebec.

Velan Inc. Reports its First Quarter 2013/14 Financial Results
Marketwire - Wed Jul 10, 3:01PM CDT
Velan Inc. (TSX: VLN) (the "Company"), a world-leading manufacturer of industrial valves, announced today its financial results for its first quarter ended May 31, 2013.

CORRECTION FROM SOURCE/Velan Inc. Reports its Year-End and Fourth Quarter 2012/13 Financial Results
Marketwire - Tue May 28, 2:51PM CDT
This document corrects and replaces the release sent earlier today at 2:34 PM EDT.

Velan Inc. Reports its Fourth Quarter and Year-End 2011/12 Financial Results
Marketwire - Tue May 28, 1:35PM CDT
Velan Inc. (TSX: VLN), a world-leading manufacturer of industrial valves, announced today its financial results for its fourth quarter and fiscal year ended February 29, 2012.

Velan Inc. (VLNSF) Stock Research Links

VLNSF Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Tomorrowland's Shanghai Return: An Electri-Lifesaver

Updated Category News Views 33

You know, every now and then, it's worth stepping out of the stock frenzy and diving into something as electrifying and far from the trading floor as Tomorrowland's latest Shanghai rendezvous. This ain't just any festival; it's the kind of hype that packs a punch—and frankly, it's a wild ride seeing such a spectacle set up shop in China, and sell out to boot. Partnering...

Continue Reading
UEG's New Advisory Board: Elevating Patient Voices

Updated Category News Views 32

Breaking Ground with Patient Representation Today's not-so-sunny forecast from Barcelona wasn't about the weather. United European Gastroenterology (UEG) rolled out its shiny new Patient Representatives Advisory Board (PRAB) during UEG Week 2026. This isn't just another committee on a never-ending list—it's a serious platform aimed at turning patient murmurs into a...

Continue Reading
ASTS Faces a Legal Countdown – Investors Take Note

Updated Category News Views 25

AST SpaceMobile's Legal Tangle AST SpaceMobile, Inc. (NASDAQ:ASTS) finds itself neck-deep in legal quagmire, with a class action lawsuit looming large. Investors who snapped up ASTS securities between March 4, 2025, and July 15, 2026, have until November 13, 2026, to reckon their grievances before the courts. This is no joke, folks. If you've lost dough because of shaky...

Continue Reading
Antheia Secures $80M for Critical Medicine Onshoring

Updated Category News Views 26

Antheia's Bold Move to Onshore Medicine Production Folks, when it comes to pharmaceuticals, it's about time someone started serious about keeping things closer to home. Antheia just landed a huge $80 million conditional commitment from the U.S. Department of War's Office of Strategic Capital. The fine print? This isn't just about building business—it's a play to secure...

Continue Reading
Faith and Resilience in China: The Legacy of the Long March

Updated Category News Views 32

History's got chapters that stick with you, and the Long March is one of those stories that shake you to your core. It all started one October evening in 1934, when more than 86,000 soldiers from the Red Army found themselves on the banks of the Yudu River. It was a scene straight out of a novel: 800-odd boats held together with coffin boards and timber beams, all set to...

Continue Reading
AEVEX Faces 48-Hour Deadline for Investor Class Action

Updated Category News Views 23

Clock Ticking on AEVEX Lawsuit Participation Ah, the twists and turns of the stock market! AEVEX Corp. (NYSE: AVEX) finds itself knee-deep in a class action lawsuit, and investors have a mere 48 hours left to make their stand as the lead plaintiff. This legal saga stems from the company's April 2026 IPO and spills into the muddy waters of securities law violations....

Continue Reading
Lundbeck's Board Leadership Transitions into New Era

Updated Category News Views 15

A Fresh Chapter for Lundbeck's Board Leadership Lundbeck is sparking some fresh boardroom energy, and it's not just business as usual. Dorothea Wenzel, who's been steering the ship, is stepping down come 2027—AGM in sight. Now, in swings Lars Fruergaard Jørgensen, ready to grab the wheel. Yeah, we've got some seasoned pharma muscles flexing here. The Before and After:...

Continue Reading

Top 5 Most Recently Viewed Articles

TKO Group Launches Major Share Buyback and Dividend Initiative

Updated Category News Views 669

TKO Group Announces Strategic Financial Moves TKO Group Holdings, Inc. (NYSE: TKO) has recently made headlines with its announcement of a remarkable share repurchase program amounting to $2 billion. Alongside this significant initiative, the company is introducing a quarterly cash dividend that is projected to reach $75 million. These strategic financial maneuvers reflect...

Continue Reading
An Insightful Look at Warner Bros. Discovery's Declining Short Interest

Updated Category News Views 64

Understanding Warner Bros. Discovery's Short Interest Trends Warner Bros. Discovery (WBD) has seen a noteworthy drop in its short percent of float, falling by 11.22% since the last report. Currently, the company reports that there are 101.75 million shares sold short, representing about 4.67% of all available shares for trading. Interestingly, based on the current trading...

Continue Reading
Avobis Bio Advances Clinical Trials for Innovative Therapy Solutions

Updated Category News Views 185

Avobis Bio Unveils Breakthrough in Clinical Trial for AVB-114 Avobis Bio LLC, a pioneering company focused on developing innovative implantable cell therapies, has made a remarkable stride by completing the primary analysis of the STOMP-II randomized clinical trial targeting Crohn's perianal fistulas. This analysis brings with it exciting prospects for FDA interaction and...

Continue Reading
Innovative Bait Accessory Enhances Fishing Experience

Updated Category News Views 239

Revolutionizing Fishing with a New Bait Accessory Fishing is more than just a hobby; it's a passion for many outdoor enthusiasts. That's why the recent invention of the E Z BAIT accessory is creating waves in the angling community. Designed for all fishing lovers, it aims to keep your bait right where you need it without missing a beat. Convenience at Your Fingertips...

Continue Reading
Oncoinvent ASA: Advancing Cancer Therapies with Financial Focus

Updated Category News Views 158

Oncoinvent ASA's Periodic Performance Highlights Oncoinvent is making strides in the oncology sector, particularly with its Phase 2 trial for ovarian cancer. This clinical-stage biotechnology company is diligently focusing on expanding its research scope while ensuring sound financial management practices. Their primary product, Radspherin®, is a radiopharmaceutical...

Continue Reading